
Pegcetacoplan Sustains Proteinuria Reductions in C3G, IC-MPGN at 52 Weeks
Extended data from the phase 3 VALIANT trial support the sustained efficacy and safety of pegcetacoplan (Empaveli) in patients with C3 glomerulopathy (C3G) or idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN), including …